Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The antitumor effects of interferon

  • 20 Accesses

Abstract

Interferons show antitumor activity in patients with various malignancies. The mechanism(s) of the antitumor effects are not altogether clear. In one experimental animal model discussed herein, mice were injected with Friend erythroleukemia cells and treated with mouse interferon α/β. The results suggest that interferon does not act directly on the tumor cells but acts via host mechanisms that are still ill defined.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Haglund S, Lundquist P G, Cantell Ket al: Interferon therapy in juvenile laryngeal papillomatosis.Arch Otolaryng 107, 327 (1981).

  2. 2.

    Bomholt A: Interferon therapy for laryngeal papillomatosis in adults.Arch Otolaryng 109, 550 (1983).

  3. 3.

    McCabe B F, Clark K F: Interferon and laryngeal papillomatosis. The Iowa experience.ANN Otol Rhinol Laryng 92, 2 (1983).

  4. 4.

    Ikic D, Bosnic N, Smerdel S, Jusci D, Soos E, Delimar N: Double-blind clinical study with human leukocyte interferon in the therapy of condyloma acuminata, in Ikic D (ed):Proc Symp Clinical Use of Interferon, Zagreb, pp. 229–233 (1975).

  5. 5.

    Schonfeld A, Nitke S, Schattner A, Wallach D, Crespi M, Hahn T, Levair H, Yarden O, Shoham J, Doerner T, Revel M: Intramuscular human interferon-β injections in treatment of condyloma acuminata.Lancet i, 1038 (1984).

  6. 6.

    Gall S A, Hughes C E, Trofatter K: Interferon for the therapy of condyloma acuminatum.Am J Obstet Gynec 153, 157 (1985).

  7. 7.

    Ho M, Pazin G J, White L T, Haverkos H, Weschler R L, Breinig M K, Cantell K, Armstrong J A: Intralesional treatment of warts with interferon-α and its long-term effect on NK cell activity, in De Maeyer E, Galasso G and Schellekens H (eds):The Biology of the Interferon System, pp. 361–365. Amsterdam, Elsevier/North-Holland Biomedical Press (1981).

  8. 8.

    Quesada J R, Reuben J, Manning J T, Hersh E M, Gutterman J U: Alpha interferon for induction of remission in hairy-cell leukemia.New Engl J Med 310, 15 (1984).

  9. 9.

    Ratain M J, Golomb H M, Vardiman J W, Vokes E E, Jacobs R H, Daly K: Treatment of hairy cell leukemia with recombinant alpha2 interferon.Blood 65, 644 (1985).

  10. 10.

    Jacobs A D, Champlin R E, Golde D W: Recombinant α-2-interferon for hairy cell leukemia.Blood 65, 1017 (1985).

  11. 11.

    Ahre A, Björkholm M, Mellstedt H, Brenning G, Engstedt L, Gahrton G, Gyllenhammar H, Holm G, Johansson B, Järnmark M, Karnström L, Killander A, Lerner R, Lockner D, Lönnqvist B, Nilsson B, Simonsson B, Stalfelt A M, Strander H, Svedmyr E, Wadman B, Wedelin C: Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the myeloma group of central Sweden.Cancer Treatment Rep 68, 1331 (1984).

  12. 12.

    Costanzi J J, Cooper M R, Scarffe J H, Ozer H, Grubbs S S, Ferraresi R W, Pollard R B, Spiegel R J: Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma.J Clin Oncol 3, 654 (1985).

  13. 13.

    Krown S E, Real F X, Cunningham-Rundles S, Myskowski P L, Koziner B, Fein S, Mittelman A, Oettgen H F, Safai B: Preliminary observations on the effect of recombinant leukocyte α interferon in homosexual men with Kaposi's sarcoma.New Engl J Med 308, 1071 (1983).

  14. 14.

    Groopman J E, Gottlieb M S, Goodman J, Mitsuyasu R T, Conant M A, Prince H, Fahey J L, Derezin M, Weinstein W M, Casavante C, Rothman J, Rudnick S A, Volberding P A: Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome.Ann Int Med 100, 671 (1984).

  15. 15.

    Gelmann E P, Preble O T, Steis R, Lane H C, Rook A H, Wesley M, Jacob J, Fauci A, Masur H, Longo D: Human lymphoblastoid interferon treatment of Kaposi's sarcoma in the acquired immune deficiency syndrome. Clinical response and prognostic parameters.Am J Med 78, 737 (1985).

  16. 16.

    Rios A, Mansell P W A, Newell G R, Reuben J M, Hersh E M, Gutterman J U: Treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma with lymphoblastoid interferon.J Clin Oncol 3, 506 (1985).

  17. 17.

    Louie A C, Gallagher J G, Sikora K, Levy R, Rosenberg S A, Merigan T C: Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma.Blood 58, 712 (1981).

  18. 18.

    Foon K A, Sherwin S A, Abrams P G, Longo D L, Fer M F, Stevenson H C, Ochs J J, Bottino G C, Schoenberger C S, Zeffren J, Jaffe E S, Oldham R K: Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte α interferon.New Engl J Med 311, 1148 (1984).

  19. 19.

    Quesada J R, Hawkins M, Horning S, Alexanian R, Borden E, Merigan T, Adams F, Gutterman J U: Collaborative phase I–II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma.Am J Med 77, 427 (1984).

  20. 20.

    Horning S J, Merigan T C, Krown S E, Gutterman J U, Louie A, Gallagher J, McCravey J, Abramson J, Cabanillas F, Oettgen H, Rosenberg S A: Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the American Cancer Society trial.Cancer 56, 1305 (1985).

  21. 21.

    Misset J L, Mathé G, Gastiaburu J, Goutner A, Dorval T, Gouveia J, Hayat M, Jasmin C, Schwarzenberg L, Machover D, Ribaud P, De Vassal F: Treatment of lymphoid neoplasisa with interferon. II. Human leucocyte α-interferon in chronic lymphatic leukemia (CLL). Phase I–II trial.Anticancer Res 2, 67 (1982).

  22. 22.

    Talpaz M, Mavligit G, Keating M, Walters R S, Gutterman J U: Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia.Ann Int Med 99, 789 (1983).

  23. 23.

    Talpaz M, McCredie K B, Mavligit G M, Gutterman J U: Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia.Blood 62, 689 (1983).

  24. 24.

    Foon K A, Bottino G C, Abrams P G, Fer M F, Longo D L, Schoenberger C S, Oldham R K: Phase II trial of recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia.Am J Med 78, 216 (1985).

  25. 25.

    Bunn P A, Foon K A, Ihde D C, Longo D L, Eddy J, Winkler C F, Veach S R, Zeffren J, Sherwin S, Oldham R: Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas.Ann Int Med 101, 484 (1984).

  26. 26.

    Quesada J R, Swanson D A, Trindade A, Gutterman J U: Renal cell carcinoma: antitumor effects of leukocyte interferon.Cancer Res 43, 940 (1983).

  27. 27.

    Marumo K, Murai M, Hayakawa M, Tazaki H: Human lymphoblastoid interferon therapy for advanced renal cell carcinoma.Urology 24, 567 (1984).

  28. 28.

    Magnusson K, Christophersen I S, Jordal R, Holm H M, Mygind T: Interferon therapy in recurrent renal carcinoma.Acta Med Scand 213, 221 (1983).

  29. 29.

    deKernion J B, Sarna G, Figlin R, Lindner A, Smith R B: The treatment of renal cell carcinoma with human leukocyte alpha-interferon.J Urol 130, 1063 (1983).

  30. 30.

    Neidhart J A, Gagen M M, Young D, Tuttle R, Melink T J, Ziccarelli A, Kisner D: Interferon-α therapy of renal cancer.Cancer Res 44, 4140 (1984).

  31. 31.

    Kirkwood J M, Harris J E, Vera R, Sandler S, Fischer D S, Khandekar J, Ernstoff M S, Gordon L, Lutes R, Bonomi P, Lytton B, Cobleigh M, Taylor S J IV: A randomized study of low and high doses of leukocyte α-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial.Cancer Res 45, 863 (1985).

  32. 32.

    Vugrin D, Hood L, Taylor W, Laszlo J: Phase II study of human lymphoblastoid interferon in patients with advanced renal carcinoma.Cancer Treatment Rep 69, 817 (1985).

  33. 33.

    Edsmyr F, Espoti P L, Andersson L, Steineck G, Lagergren C, Strander H: Interferon therapy in disseminated renal cell carcinoma.Radiother Oncol 4, 21 (1985).

  34. 34.

    Quesada J R, Rios A, Swanson D, Trown P, Gutterman J U: Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma.J Clin Oncol 3, 1522 (1985).

  35. 35.

    Nilsonne U, Strander H: Traitement de l'ostéosarcome par l'interféron et la chirurgie différenciée.Rev Chir Orthopéd 67, 193 (1981).

  36. 36.

    Borden E C, Holland J F, Dao T L, Gutterman J U, Wiener L, Chang Y-C, Patel J: Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial.Ann Int Med 97, 1 (1982).

  37. 37.

    Sherwin S A, Mayer D, Ochs J J, Abrams P G, Knost J A, Foon K A, Fein S, Oldham R K: Recombinant leukocyte A interferon in advanced breast cancer. Results of a phase II efficacy trial.Ann Int Med 98, 598 (1983).

  38. 38.

    Nethersell A, Smedley H, Katrak M, Wheeler T, Sikora K: Recombinant interferon in advanced breast cancer.Br J Cancer 49, 615 (1984).

  39. 39.

    Borden E C, Balkwill F R: Preclinical and clinical studies of interferons and interferon inducers in breast acner.Cancer 53, 783 (1984).

  40. 40.

    Padmanabhan N, Balkwill F R, Bodmer J G, Rubens R D: Recombinant DNA human interferon alpha 2 in advanced breast cancer: a phase 2 trial.Br J Cancer 51, 55 (1985).

  41. 41.

    Einhorn N, Cantell K, Einhorn S, Strander H: Human leukocyte interferon therapy for advanced ovarian carcinoma.Am J Clin Oncol 5, 167 (1982).

  42. 42.

    Freedman R S, Gutterman J U, Wharton J T, Rutledge F N: Leukocyte interferon (IFNα) in patients with epithelial ovarian carcinoma.J Biol Response Modif 2, 133 (1983).

  43. 43.

    Berek J S, Hacker N F, Lichtenstein A, Jung T, Spina C, Knox R M, Brady J, Greene T, Ettinger L M, Lagasse L D, Bonnem E M, Spiegel R J, Zighelboim J: Stage III epithelial ovarian cancer: a gynecologic oncology group study.Cancer Res 45, 4447 (1985).

  44. 44.

    Ikic D, Kirhmajer V, Maricic Z, Jusic D, Krusic J, Knezevic M, Rode B, Soos E: Application of human leukocyte interferon in patients with carcinoma of the uterine cercix.Lancet i, 1027 (1981).

  45. 45.

    Retsas S, Priestman T J, Newton K A, Westbury G: Evaluation of human lymphoblastoid interferon in advanced malignant melanoma.Cancer 51, 273 (1983).

  46. 46.

    Creagan E T, Ahmann D L, Green S J, Long H J, Rubin J, Schutt A J, Dziewanowshi Z E: Phase II study of recombinant leukocyte A interferon (rIFN-αA) in disseminated malignant melanoma.Cancer 54, 2844 (1984).

  47. 47.

    Flodgren P, Borgström S, Jönsson P E, Lindström C, Sjögren H O: Metastatic malignant melanoma: regression induced by combined treatment with interferon (HuIFN-α(Le)) and cimetidine.Int J Cancer 32, 657 (1983).

  48. 48.

    Krown S E, Burk M W, Kirkwood J M, Kerr D, Morton D L, Oettgen H F: Human leukocyte (alpha) interferon in metastatic malignant melanoma: the American Cancer Society phase II trial.Cancer Treatment Rep 68, 723 (1984).

  49. 49.

    Goldberg R M, Ayoob M, Silgals R, Ahlgren J D, Neefe J R: Phase II trial of lymphoblastoid interferon in metastatic malignant melanoma.Cancer Treatment Rep 69, 813 (1985).

  50. 50.

    Hersey P, Hasic E, MacDonald M, Edwards A, Spurling A, Coates A S, Milton G W, McCarthy W H: Effects of recombinant leukocyte interferon (rIFN-αA) on tumour growth and immune responses in patients with metastatic melanoma.Br J Cancer 51, 815 (1985).

  51. 51.

    Kirkwood J M, Ernstoff M S, Davis C A, Reiss M, Ferraresi R, Rudnick S A: Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers.Ann Int Med 103, 32 (1985).

  52. 52.

    Flodgren P, Malström P, Azelsson B, Boketoft A, Borgström S, Sjögren H O: Immune functions in melanoma patients during treatment with interferon (HuIFN-α-Le)) alone or in combination with cimetidine.Anticancer Res 5, 197 (1985).

  53. 53.

    Boëthius J, Blomgren H, Collins V P, Greitz T, Strander H: The effect of systemic human interferon-alpha administration to patients with glioblastoma multiforme.Acta Neurochir 68, 239 (1983).

  54. 54.

    Hirakawa K, Ueda S, Nakagawa Y, Suzuki K, Fukuma S, Kita M, Imanishi J, Kishida T: Effect of human leukocyte interferon on malignant brain tumors.Cancer 51, 1976 (1983).

  55. 55.

    Nakagawa Y, Hirakawa K, Ueda S, Suzuki K, Fukuma S, Kishida T, Imanishi J, Amagai T: Local administration of interferon for malignant brain tumors.Cancer Treatment Rep 67, 833 (1983).

  56. 56.

    Nagai M, Arai T: Clinical effect of interferon in malignant brain tumours.Neurosurg Rev 7, 55 (1984).

  57. 57.

    Mahaley M S Jr, Urso M B, Whaley R A, Blue M, Williams T E, Guaspari A, Selker R G: Immunobiology of primary intracranial tumors.J Neurosurg 63, 719 (1985).

  58. 58.

    Rustin G J S, Kaye S B, Williams C J, Newlands E S, Bagshawe K D, Toy J L: Response of differentiated but not anaplastic teratoma to interferon.Br J Cancer 50, 611 (1984).

  59. 59.

    Treuner J, Niethammer D, Dannecker G, Jobke A, Aldenhoff P, Kremens B, Nessler G, Bömer H: Treatment of nasopharyngeal carcinoma in children with fibroblast interferon, in Grundmannet al. (eds):Cancer Campaign, Vol. 5, pp. 309–316. Stuttgart, Gustav Fischer (1981).

  60. 60.

    Connors J M, Andiman W A, Howarth C B, Liu E, Merigan T C, Savage M E, Jacobs C: Treatment of nasopharyngeal carcinoma with human leukocyte interferon.J Clin Oncol 3, 813 (1985).

  61. 61.

    Sawada T, Takamatsu T, Tanaka T, Mino M, Fujita K, Kusunoki T, Arizono N, Fukuda M, Kishida T: Effects of intralesional interferon on neuroblastoma: changes in histology and DNA content distribution of tumor masses.Cancer 48, 2143 (1981).

  62. 62.

    Öberg K, Funa K, Alm G: Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome.New Engl J Med 309, 129 (1983).

  63. 63.

    Öberg K, Lindström H, Alm G, Lundqvist G: Successful treatment of therapy-resistant pancreatic cholera with human leucocyte interferon.Lancet i, 725 (1985).

  64. 64.

    Gresser I, Tovey M G: Antitumor effects of interferon.Biochim Biophys Acta 516, 231 (1978).

  65. 65.

    Gresser I: Antitumor effects of interferon, in Becker F (ed):Cancer—a comprehensive treatise—Chemotherapy, Vol. 5, pp. 521–571. New York, Plenum Press (1977).

  66. 66.

    Gresser I: How does interferon inhibit tumour growth?Phil Trans R Soc Lond B299, 69 (1982).

  67. 67.

    Gresser I, Coppey J, Fontaine-Brouty-Boyé D, Falcoff E, Falcoff R, Zajdela F, Bourali C, Thomas M T: The effect of interferon preparations on Friend leukemia in mice, in Wolstenholme G E W and O'Conner M (eds):Ciba Found Symp Interferon, p. 240 (1967).

  68. 68.

    Gresser I, Bourali C, Lévy J P, Fontaine-Brouty-Boyé D, Thomas M T: Increased survival in mice inoculated with tumor cells and treated with interferon preparations.Proc Natl Acad Sci 63, 51 (1969).

  69. 69.

    Gresser I, Bourali C: Antitumor effects of interferon preparations in mice.J Natl Cancer Inst 45, 365 (1970).

  70. 70.

    Gresser I, Bourali-Maury C: Inhibition by interferon preparations of a solid malignant tumour and pulmonary metastases in mice.Nature New Biol 236, 78 (1972).

  71. 71.

    Gresser I, De Maeyer-Guignard J, Tovey M G, De Maeyer E: Electrophoretically pure mouse interferon exerts multiple biologic effects.Proc Natl Acad Sci USA 76, 5308 (1979).

  72. 72.

    Paucker K, Cantell K, Henle W: Quantitative studies on viral interference in suspended L cells. III. Effect of interfering viruses and interferon on the growth rate of cells.Virology 17, 324 (1962).

  73. 73.

    Gresser I, Brouty-Boyé D, Thomas M T, Macieira-Coelho A: Interferon and cell division. I. Inhibition of the multiplication of mouse leukemia L 1210 cellsin vitro by interferon preparations.Proc Natl Acad Sci 66, 1052 (1970).

  74. 74.

    Gresser I, Brouty-Boyé D, Thomas M T, Macieira-Coelho A: Interferon and cell division. II. Influence of various experimental conditions on the inhibition of L 1210 cell multiplicationin vitro by interferon preparations.J Natl Cancer Inst 45, 1145 (1970).

  75. 75.

    Macieira-Coelho A, Brouty-Boyé D, Thomas M T, Gresser I: Interferon and cell division. III. Effect of interferon on the division cycle of L 1210 cellsin vitro.J Cell Biol 48, 415 (1971).

  76. 76.

    Gresser I Thomas M T, Brouty-Boyé D: Effects of interferon treatment of L 1210 cellsin vitro on tumour and colony formation.Nature 231, 20 (1971).

  77. 77.

    Gresser I, Thomas M T, Brouty-Boyé D, Macieira-Coelho A: Interferon and cell division. V. Titration of the anticellular action of interferon preparations.Proc Soc Exp Biol Med 137, 1258 (1971).

  78. 78.

    Lindahl-Magnusson P, Leary P, Gresser I: Interferon and cell division. VI. Inhibitory effect of interferon on the multiplication of mouse embryo and mouse kidney cells in primary cultures.Proc Soc Exp Biol Med 138, 1044 (1971).

  79. 79.

    Gresser I, Bandu M T, Tovey M, Bodo G, Paucker K, Stewart W II: Interferon and cell division. VII. Inhibitory effect of highly purified interferon preparations on the multipliction of leukemia L 1210 cells.Proc Soc Exp Biol Med 142, 7 (1973).

  80. 80.

    Brouty-Boyé D, Macieira-Coelho A, Fiszman M, Gresser I: Interferon and cell division. VIII. Effect of interferon on macromolecular synthesis in L 1210 cellsin vitro.Int J Cancer 12, 250 (1973).

  81. 81.

    Gresser I, Bandu M T, Brouty-Boyé D: Interferon and cell division. IX. Interferon-resistant L 1210 cells: characteristics and origin.J Natl Cancer Inst 52, 553 (1974).

  82. 82.

    Tovey M, Brouty-Boyé D, Gresser I: Early effect of interferon on mouse leukemia cells cultivated in a chemostat.Proc Natl Acad Sci USA 72, 2265 (1975).

  83. 83.

    Tovey M G, Rochette-Egly C, Castagna M: Correlation between growth rate, cell density, and intracellular concentrations of cyclic nucleotides in chemostat cultures of mouse L 1210 cells.J Cell Physiol 105, 363 (1980).

  84. 84.

    Stewart W E II, Gresser I, Tovey M G, Bandu M T, Le Goff S: Identification of the cell multiplication inhibitory factors in interferon preparations as interferons.Nature 262, 300 (1976).

  85. 85.

    D'Hooghe M C, Brouty-Boyé D, Malaise E P, Gresser I: Interferon and cell division. XII. Prolongation by interferon of the intermitotic time of mouse mammary tumor cellsin vitro. Microcinematographic analysis.Exp Cell Res 105, 73 (1977).

  86. 86.

    McNeill T A, Gresser I: Inhibition of haemopoietic colony growth by interferon preparations from different sources.Nature New Biol 244, 173 (1973).

  87. 87.

    Lindahl P, Leary P, Gresser I: Enhancement by interferon of the expression of surface antigens on murine leukemia L 1210 cells.Proc Natl Acad Sci USA 70, 2785 (1973).

  88. 88.

    Huet C, Gresser I, Bandu M T, Lindahl P: Increased binding of concanavalin A to interferon-treated murine leukemia L 1210 cells.Proc Soc Exp Biol Med 147, 52 (1974).

  89. 89.

    Killander D, Lindahl P, Lundin L, Leary P, Gresser I: Relationship between the enhanced expression of histocompatibility antigens on interferon-treated L 1210 cells and their position in the cell cycle.Eur J Immun 6, 56 (1976).

  90. 90.

    Fellous M, Kamoun M, Gresser I, Bono R: Enhanced expression of HLA antigens and β2-microglobulin on interferon-treated human lymphoid cells.Eur J Immun 9, 446 (1979).

  91. 91.

    Fellous M, Bono R, Hyafil F, Gresser I: Interferon enhances the amount of membrane-bound β2-microglobulin and its release from human Burkitt cells.Eur J Immun 11, 254 (1981).

  92. 92.

    Brouty-Boyé D, Zetter B R: Inhibition of cell motility by interferon.Science 208, 516 (1980).

  93. 93.

    Brouty-Boyé D, Gresser I: Reversibility of the transformed and neoplastic phenotype. I. Progressive reversion of the phenotype of X-ray-transformed C3H/10T1/2 cells under prolonged treatment with interferon.Int J Cancer 28, 165 (1981).

  94. 94.

    Carter W A, Leong S S, Horoszewicz J S: Human fibroblast interferon in the control of neoplasia, in Chandra P (ed):Antiviral Mechanisms in the Control of Neoplasia, p. 663. New York, Plenum Press (1978).

  95. 95.

    Balkwill F, Taylor-Papadimitriou J, Fantes K H, Sebesteny A: Human lymphoblastoid interferon can inhibit the growth of human breast cancer xenografts in athymic nude mice.Eur J Cancer 16, 569 (1980).

  96. 96.

    Balkwill F R, Moodie E M, Freedman V, Fantes K H: Human interferon inhibits the growth of established human breast tumours in the nude mouse.Int J Cancer 30, 231 (1982).

  97. 97.

    Aguet M: High-affinity binding of125I-labelled mouse interferon to a specific cell surface receptor.Nature 284, 459 (1980).

  98. 98.

    Wietzerbin J, Merlin G, Gaudelet C, Falcoff E: Specific binding of125I-mouse interferon gamma to high affinity receptors in mouse L 1210 cells sensitive and resistant to interferon alpha/beta, in De Maeyer E and Schellekens H (eds):The Biology of the Interferon System, p. 425. Amsterdam, Elsevier (1985).

  99. 99.

    Gresser I, Maury C, Brouty-Boyé D: On the mechanism of the antitumour effect of interferon in mice.Nature 239, 167 (1972).

  100. 100.

    Belardelli F, Gresser I, Maury C, Maunoury M T: Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. I.Int J Cancer 30, 813 (1982).

  101. 101.

    Belardelli F, Gresser I, Maury C, Maunoury M T: Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. II. Role of host mechanisms.Int J Cancer 30, 821 (1982).

  102. 102.

    Belardelli F, Gresser I, Maury C, Duvillard P, Prade M, Maunoury M T: Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. III. Inhibition of growth and necrosis of tumors implanted subcutaneously.Int J Cancer 31, 649 (1983).

  103. 103.

    Gresser I: How does interferon inhibit tumor growth? In Gresser I (ed):Interferon 6, p. 93 London, Academic Press (1985).

  104. 104.

    Gresser I: Interferon and the immune system, in Fougereau M and Dausset J (eds):Progress in Immunology IV, pp. 710–719. Fourth International Congress of Immunology. Immunology 80. London, Academic Press (1980).

  105. 105.

    Gresser I, Bourali-Maury C: The antitumor effect of interferon in lymphocyte and macrophage-depressed mice.Proc Soc Exp Biol Med 144, 896 (1973).

  106. 106.

    Merigan T C, Sikora K, Breeden J H, Levy R, Rosenberg S A: Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma.New Engl J Med 299, 1449 (1978).

  107. 107.

    Einhorn S, Ahre A, Blomgren H, Johansson B, Mellstedt H, Strander H: Interferon and natural killer cell activity in multiple myeloma. Lack of correlation between interferon-induced enhancement of natural killer activity and clincal response to human interferon.Int J Cancer 30, 167 (1982).

  108. 108.

    Einhorn S, Blomgren H, Strander H, Wasserman J: Influence of human interferon-α therapy on cytotoxic functions of blood lymphocytes.Cancer Immun Immunother 16, 77 (1983).

  109. 109.

    Stolpen A H, Guinan E C, Fiers W, Pober J S: Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers.J Exp Med (in press).

  110. 110.

    Collins T, Lapierre L A, Fiers W, Strominger J J, Pober J S: Recombinant human tumor necrosis factor increasesmRNA levels and surface expression of HLA-A, B antigens in vascular endothelial cells and dermal fibroblastsin vitro.Proc Natl Acad Sci USA 83, 446 (1986).

Download references

Author information

Correspondence to Ion Gresser.

Additional information

This article is dedicated to the memory of Professor John F. Enders.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gresser, I. The antitumor effects of interferon. Med. Oncol. & Tumor Pharmacother. 3, 223 (1986). https://doi.org/10.1007/BF02934998

Download citation

Key words

  • Interferon
  • Antitumor
  • Patients
  • Mice